US$ 28.40
glp 1 effect on heart The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action Direct cardiovascular effects of glucagon
Description
Shop our selection of natural supplements and products

The approval gives Novo Nordisk a head start over chief rival Eli Lilly, which is racing to launch its own obesity pill.

GLP-1 drugs are remarkably effective at reducing visceral fat, which accumulates around the waist, surrounding and invading the liver, heart, and pancreas
Tirzepatide (Zepbound/Mounjaro): A dual GLP-1/GIP receptor agonist undergoing evaluation for MASH after demonstrating significant liver fat reduction in studies.Retatrutide: A "triple agonist" targeting GLP-1, GIP, and glucagon (GCGR) receptors, which has shown "unprecedented" efficacy in weight loss and is being evaluated for metabolic diseases including MASH
